Eastwood Bio-Medical Canada EBIT

Eastwood Bio-Medical Canada's ebit stands at $-460K as of July 2024. That compares with $-290K in the prior-year period — down 58.7% year over year. That is below the sector sector average of $2.5T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Eastwood Bio-Medical Canada reported $-460K in EBIT versus $-290K a year earlier — a 58.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Eastwood Bio-Medical Canada sits lower the its sector benchmark ($2.5T) with a EBIT of $-460K. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-290K in the prior-year period — down 58.7% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Eastwood Bio-Medical Canada's EBIT evolved across reporting periods, while the comparison chart places EWOOF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.